Metropolis Healthcare Ltd Share Price (METROPOLIS)

Metropolis Healthcare's ROE Raises Concerns - 25 Apr, 2024

Metropolis Healthcare's low Return on Equity (ROE) of 12% raises concerns about the company's profitability and reinvestment strategy. The low earnings growth number doesn't reflect the high profit retention, but analysts expect earnings to gain momentum.

HDFC Mutual Fund holds 6.65% stake in Metropolis Healthcare - 23 Apr, 2024

As of March 2024, HDFC Mutual Fund holds 34,06,307 equity shares equivalent to 6.65% of Metropolis Healthcare Ltd. The company reported a revenue of Rs 291 crore and net profit of Rs 27 crore in Q3FY24.

Analysts Expect Limited Upside for Metropolis Healthcare Stock - 22 Apr, 2024

Shares of Metropolis Healthcare have underperformed over the past four years, with a spike in stock prices following Covid-19 that has since fizzled out. Analysts expect some recovery but limited upside.

Metropolis Healthcare Shares Surge on Debt-Free Status and Strong Q4 Update - 15 Apr, 2024

Metropolis Healthcare becomes debt-free, reports strong Q4 results, and sees massive buying in call options. Axis Securities gives the company a buy call with a target price of Rs 2135.

Metropolis Healthcare Reports Strong Q4 Performance and Achieves Debt-Free Status - 12 Apr, 2024

Metropolis Healthcare achieved a debt-free status as of March 31, 2024, following the repayment of debt during the quarter. The company reported a 15% YoY rise in core business revenue, driven by volume growth and an increase in Revenue Per Patient (RPP). Additionally, their Business-to-Consumer (B2C) revenues saw a robust growth of approximately 18% YoY in Q4 FY24.

Metropolis Healthcare Reports Strong Q4 FY24 Results - 11 Apr, 2024

Metropolis Healthcare reported a 15% YoY increase in core business revenue for Q4 FY24, driven by growth in specialty tests and premium wellness segments. The company also experienced an overall 10% YoY increase in revenue despite the prolonged holiday period. B2C revenues jumped 18% YoY, while EBIDTA margins showed a consistent upward trend. Metropolis Healthcare is now debt-free and has enhanced its market share in core geographies.

Diagnostic Companies to Register 10-11% Growth in Revenue by FY2025 - 10 Apr, 2024

A study by CRISIL predicts that diagnostic companies, including Metropolis Healthcare, are set to register a growth of 10-11% in revenue by financial year 2025 due to an increase in the number of patients and improving revenue per patient.

BNP Paribas Securities Gives Buy Call on Metropolis Healthcare Ltd - 05 Apr, 2024

BNP Paribas Securities has given a buy call on Metropolis Healthcare Ltd with a target price of Rs 1969. For the quarter ended December 31, 2023, the company reported a consolidated total income of Rs 293.42 crore and net profit after tax of Rs 27.29 crore.

Founder of Metropolis Healthcare Sells Shares Worth ₹62m - 04 Apr, 2024

Sushil Shah, the Founder & Executive Chairman of Metropolis Healthcare Limited, sold about ₹62m worth of shares at an average price of ₹1,767. The sale accounted for 0.4% of their holding and was made at around the current market price.

Metropolis Healthcare's High P/E Ratio Raises Concerns - 28 Mar, 2024

Metropolis Healthcare's P/E ratio of 71x is significantly higher than the market average, indicating a potential overvaluation. The company's declining earnings compared to its peers may be a cause for concern.